**About the Editor**

#### **Elixabet Lopez-Lopez**

Dr. Elixabet Lopez-Lopez is an assistant professor at the Department of Biochemistry and Molecular Biology at the University of the Basque Country (UPV/EHU), and she is affiliated with the Biocruces Bizkaia Health Research Institute. She has dedicated her career so far to the search for pharmacogenomics markers to improve the treatment of pediatric oncology patients. During her PhD training and subsequent postdoctoral experience at the UPV/EHU (Spain), her main focus was on genetic variants associated with adverse drug reactions and response in pediatric acute lymphoblastic leukemia and osteosarcoma patients. She was able to find SNPs associated with drug toxicity by studying candidate genes in the methotrexate and vincristine pathways. Additionally, she was the first author in the first study to show that polymorphisms in miRNA processing genes are associated with toxicity after treatment in cancer patients. Later, in the context of her work as a postdoctoral fellow at St. Jude Children's Research Hospital (USA), she was able to analyze genome-wide expression and regulation (miRNAs, methylation, SNPs, and copy number alterations) in association with methotrexate response in acute lymphoblastic leukemia patients. At her current position as part of the group "Genetics and Epigenetics of Complex Diseases", she is in charge of the research line of pharmacogenetics in childhood ALL.
